HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques

Virology

Volumn 471-473, Issue , 2014, Pages 81-92

  Thomas, Michael A ^a   Tuero, Iskra ^a   Demberg, Thorsten ^a   Vargas Inchaustegui, Diego A ^a   Musich, Thomas ^a   Xiao, Peng ^a   Venzon, David ^a   LaBranche, Celia ^b   Montefiori, David C ^b   DiPasquale, Janet ^a   Reed, Steven G ^c   DeVico, Anthony ^d   Fouts, Timothy ^e   Lewis, George K ^d   Gallo, Robert C ^d   Robert Guroff, Marjorie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Infectious Diseases Research Institute   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e Profectus BioSciences Inc   (United States)

Author keywords

Antibody dependent cellular cytotoxicity; HIV CD4i epitope; HIV vaccine; Memory B and T cells; Neutralizing antibody; Replication competent Ad; Rhesus macaque model; Systemic and mucosal adaptive immunity

Indexed keywords

ADENOVIRUS VECTOR; CD4 ANTIGEN; EPITOPE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOLOGICAL ADJUVANT; NEF PROTEIN; NEUTRALIZING ANTIBODY; RECOMBINANT GLYCOPROTEIN GP 120; RECOMBINANT HUMAN FLSC PROTEIN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ARTICLE; BONE MARROW CELL; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GAG GENE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; INNATE IMMUNITY; LUNG LAVAGE; MALE; MEMORY T LYMPHOCYTE; NEF GENE; NONHUMAN; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECTUM; RHESUS MONKEY; SIGNAL TRANSDUCTION; SIMIAN IMMUNODEFICIENCY VIRUS; TISSUE SECTION; VACCINE PRODUCTION; VIRAL CLEARANCE; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; B LYMPHOCYTE; BIOSYNTHESIS; GENETICS; HIV INFECTIONS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; T LYMPHOCYTE;

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA;

AIDS VACCINES; ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD4; B-LYMPHOCYTES; EPITOPES; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; MACACA MULATTA; MALE; RECTUM; T-LYMPHOCYTES; VIRAL LOAD;

EID: 84908605720     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.10.001     Document Type: Article

References (63)

1. Alter G., Moody M.A. The humoral response to HIV-1: new insights, renewed focus. J. Infect. Dis. 2010, 202(Suppl. 2):S315-S322.
2. Appledorn D.M., Patial S., McBride A., Godbehere S., Van Rooijen N., Parameswaran N., Amalfitano A. Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J. Immunol. 2008, 181:2134-2144.
3. Barnett S.W., Srivastava I.K., Kan E., Zhou F., Goodsell A., Cristillo A.D., Ferrai M.G., Weiss D.E., Letvin N.L., Montefiori D., Pal R., Vajdy M. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 2008, 22:339-348.
4. Barnett S.W., Burke B., Sun Y., Kan E., Legg H., Lian Y., Bost K., Zhou F., Goodsell A., zur Megede J., Polo J., Donnelly J., Ulmer J., Otten G.R., Miller C.J., Vajdy M., Srivastava I.K. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J. Virol. 2010, 84:5975-5985.
5. Bogers W.M., Davis D., Baak I., Kan E., Hofman S., Sun Y., Mortier D., Lian Y., Oostermeijer H., Fagrouch Z., Dubbes R., van der Maas M., Mooij P., Koopman G., Verschoor E., Langedijk J.P., Zhao J., Brocca-Cofano E., Robert-Guroff M., Srivastava I., Barnett S., Heeney J.L. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology 2008, 382:217-225.
6. Brocca-Cofano E., McKinnon K., Demberg T., Venzon D., Hidajat R., Xiao P., Daltabuit-Test M., Patterson L.J., Robert-Guroff M. Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia. Vaccine 2011, 29:3310-3319.
7. Buckner C., Gines L.G., Saunders C.J., Vojtech L., Srivastava I., Gettie A., Bohm R., Blanchard J., Barnett S.W., Safrit J.T., Stamatatos L. Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV. Virology 2004, 320:167-180.
8. Chan D.C., Kim P.S. HIV entry and its inhibition. Cell 1998, 93:681-684.
9. Coler R.N., Bertholet S., Moutaftsi M., Guderian J.A., Windish H.P., Baldwin S.L., Laughlin E.M., Duthie M.S., Fox C.B., Carter D., Friede M., Vedvick T.S., Reed S.G. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 2011, 6:e16333.
10. De Milito A., Morch C., Sonnerborg A., Chiodi F. Loss of memory (CD27) B lymphocytes in HIV-1 infection. AIDS 2001, 15:957-964.
11. DeVico A., Fouts T., Lewis G.K., Gallo R.C., Godfrey K., Charurat M., Harris I., Galmin L., Pal R. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc. Natl. Acad. Sci. USA 2007, 104:17477-17482.
12. Decker J.M., Bibollet-Ruche F., Wei X., Wang S., Levy D.N., Wang W., Delaporte E., Peeters M., Derdeyn C.A., Allen S., Hunter E., Saag M.S., Hoxie J.A., Hahn B.H., Kwong P.D., Robinson J.E., Shaw G.M. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J. Exp. Med. 2005, 201:1407-1419.
13. Demberg T., Florese R.H., Heath M.J., Larsen K., Kalisz I., Kalyanaraman V.S., Lee E.M., Pal R., Venzon D., Grant R., Patterson L.J., Korioth-Schmitz B., Buzby A., Dombagoda D., Montefiori D.C., Letvin N.L., Cafaro A., Ensoli B., Robert-Guroff M. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J. Virol. 2007, 81:3414-3427.
14. Demberg T., Brocca-Cofano E., Xiao P., Venzon D., Vargas-Inchaustegui D., Lee E.M., Kalisz I., Kalyanaraman V.S., Dipasquale J., McKinnon K., Robert-Guroff M. Dynamics of memory B-cell populations in blood, lymph nodes, and bone marrow during antiretroviral therapy and envelope boosting in simian immunodeficiency virus SIVmac251-infected rhesus macaques. J. Virol. 2012, 86:12591-12604.
15. Demberg T., Brocca-Cofano E., Kuate S., Aladi S., Vargas-Inchaustegui D.A., Venzon D., Kalisz I., Kalyanaraman V.S., Lee E.M., Pal R., DiPasquale J., Ruprecht R.M., Montefiori D.C., Srivastava I., Barnett S.W., Robert-Guroff M. Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques. Virology 2013, 440:210-221.
16. Dey A.K., Burke B., Sun Y., Sirokman K., Nandi A., Hartog K., Lian Y., Geonnotti A.R., Montefiori D., Franti M., Martin G., Carfi A., Kessler P., Martin L., Srivastava I.K., Barnett S.W. Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein. PLoS One 2012, 7:e30233.
17. Edmonds T.G., Ding H., Yuan X., Wei Q., Smith K.S., Conway J.A., Wieczorek L., Brown B., Polonis V., West J.T., Montefiori D.C., Kappes J.C., Ochsenbauer C. Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 2010, 408:1-13.
18. Fouts T.R., Tuskan R., Godfrey K., Reitz M., Hone D., Lewis G.K., DeVico A.L. Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. J. Virol. 2000, 74:11427-11436.
19. Gibson M., Tiensiwakul P., Khoobyarian N. Adenovirus fiber protein (FP) functions as a mitogen and an adjuvant. Cell Immunol. 1982, 73:397-403.
20. 251. J. Immunol. 2005, 174:2185-2189.
21. Gomez-Roman V.R., Florese R.H., Patterson L.J., Peng B., Venzon D., Aldrich K., Robert-Guroff M. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J. Immunol. Methods 2006, 308:53-67.
22. Guan Y., Pazgier M., Sajadi M.M., Kamin-Lewis R., Al-Darmarki S., Flinko R., Lovo E., Wu X., Robinson J.E., Seaman M.S., Fouts T.R., Gallo R.C., DeVico A.L., Lewis G.K. Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc. Natl. Acad. Sci. USA 2013, 110:E69-E78.
23. Hansen S.G., Ford J.C., Lewis M.S., Ventura A.B., Hughes C.M., Coyne-Johnson L., Whizin N., Oswald K., Shoemaker R., Swanson T., Legasse A.W., Chiuchiolo M.J., Parks C.L., Axthelm M.K., Nelson J.A., Jarvis M.A., Piatak M., Lifson J.D., Picker L.J. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473:523-527.
24. Hansen S.G., Piatak M., Ventura A.B., Hughes C.M., Gilbride R.M., Ford J.C., Oswald K., Shoemaker R., Li Y., Lewis M.S., Gilliam A.N., Xu G., Whizin N., Burwitz B.J., Planer S.L., Turner J.M., Legasse A.W., Axthelm M.K., Nelson J.A., Fruh K., Sacha J.B., Estes J.D., Keele B.F., Edlefsen P.T., Lifson J.D., Picker L.J. Immune clearance of highly pathogenic SIV infection. Nature 2013, 502:100-104.
25. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., Evans D.T., Montefiori D.C., Karnasuta C., Sutthent R., Liao H.-X., DeVico A.L., Lewis G.K., Williams C., Pinter A., Fong Y., Janes H., DeCamp A., Huang Y., Rao M., Billings E., Karasavvas N., Robb M.L., Ngauy V., de Souza M., Paris R., Ferrari G., Bailer R.T., Soderberg K.A., Andrews C., Berman P.W., Frahm N., De Rosa S.C., Alpert M.D., Yates N.L., Shen X., Koup R.A., Pitisuttithum P., kaewkungwal J., Nitayaphan S., Rerks-Ngarm S., Michael N.L., Kim J.H. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. New Engl. J. Med. 2012, 366:1275-1286.
26. Hendrickx R., Stichling N., Koelen J., Kuryk L., Lipieac A., Greber U.F. Innate immunity to adenovirus. Hum Gene Ther. 2014, 25:265-284.
27. Holl V., Peressin M., Decoville T., Schmidt S., Zolla-Pazner S., Aubertin A.M., Moog C. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J. Virol. 2006, 80:6177-6181.
28. Jelicic K., Cimbro R., Nawaz F., Huang D.W., Zheng X., Yang J., Lempiciki R.A., Pascuccio M., Van Ryk D., Schwing C., Hiatt J., Okwara N., Wei D., Roby G., David A., Hwang I.Y., Kehrl J.H., Arthos J., Cicala C., Fauci A.S. The HIV-1 envelope protein gp120 impairs B cell proliferation by inducing TGF-∃1 production and FcRL4 expression. Nature Immunol. 2013, 14:1256-1265.
29. Jin X., Bauer D.E., Tuttleton S.E., Lewin S., Gettie A., Blanchard J., Irwin C.E., Safrit J.T., Mittler J., Weinberger L., Kostrikis L.G., Zhang L., Perelson A.S., Ho D.D. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 1999, 189:991-998.
30. Kanzler H., Barrat F.J., Hessel E.M., Coffman R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nature Med. 2007, 13:552-559.
31. Kim J.H., Pitisuttithum P., Kamboonruang C., Chuenchitra T., Mascola J., Frankel S.S., DeSouza M.S., Polonis V., McLinden R., Sambor A., Brown A.E., Phonrat B., Rungruengthanakit K., Duliege A.M., Robb M.L., McNeil J., Birx D.L., Thai AIDS Vaccine Evaluation Group Specific antibody responses to vaccination with bivalent CM235/SF2 gp120: detection of homologous and heterologous neutralizing antibody to subtype E (CRF01.AE) HIV type 1. AIDS Res. Hum. Retrovir. 2003, 19:807-816.
32. Kuhrt D., Faith S.A., Leone A., Rohankedkar M., Sodora D.L., Picker L.J., Cole K.S. Evidence of early B-cell dysregulation in simian immunodeficiency virus infection: rapid depletion of naïve and memory B-cell subsets with delayed reconstitution of the naïve B-cell population. J. Virol. 2010, 84:2466-2476.
33. Lee E.M., Chung H.K., Livesay J., Suschak J., Finke L., Hudacik L., Galmin L., Bowen B., Markham P., Cristillo A., Pal R. Molecular methods for evaluation of virological status of nonhuman primates challenged with simian immunodeficiency or simian-human immunodeficiency viruses. J. Virol. Methods 2010, 163:287-9428.
34. Lubeck M.D., Natuk R., Myagkikh M., Kalyan N., Aldrich K., Sinangil F., Alipanah S., Murthy S.C., Chanda P.K., Nigida S.M., Markham P.D., Zolla-Pazner S., Steimer K., Wade M., Reitz M.S., Arthur L.O., Mizutani S., Davis A., Hung P.P., Gallo R.C., Eichberg J., Robert-Guroff M. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat. Med. 1997, 3:651-658.
35. Malkevitch N.V., Patterson L.J., Aldrich M.K., Wu Y., Venzon D., Florese R.H., Kalyanaraman V.S., Pal R., Lee E.M., Zhao J., Cristillo A., Robert-Guroff M. Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses. Virology 2006, 353:83-98.
36. McDermott A.B., Mitchen J., Piaskowski S., De Souza I., Yant L.J., Stephany J., Furlott J., Watkins D.I. Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates. J. Virol. 2004, 78:3140-3144.
37. McLinden R.J., Labranche C.C., Chenine A.L., Polonis V.R., Eller M.A., Wieczorek L., Ochsenbauer C., Kappes J.C., Perfetto S., Montefiori D.C., Michael N.L., Kim J.H. Detection of HIV-1 neutralizing antibodies in a human CD4(+)/CXCR4(+)/CCR5(+) T-lymphoblastoid cell assay system. PLoS One 2013, 8:e77756.
38. Molinier-Frenkel V., Lengagne R., Gaden F., Hong S.S., Choppin J., Gahery-Segard H., Boulanger P., Guillet J.G. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J. Virol. 2002, 76:127-135.
39. Montefiori D.C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Prot. Immunol. 2004, 64:12.11.1-12.11.17.
40. Morrow M.P., Yan J., Pankhong P., Ferraro B., Lewis M.G., Khan A.S., Sardesai N.Y., Weiner D.B. Unique Th1/Th2 phenotypes induced during priming and memory phases by use of interleukin-12 (IL-12) or IL-28B vaccine adjuvants in rhesus macaques. Clin. Vac. Immunol. 2010, 17:1493-1499.
41. Mudd P.A., Martins M.A., Ericsen A.J., Tully D.C., Power K.A., Bean A.T., Piaskowski S.M., Duan L., Seese A., Gladden A.D., Weisgrau K.L., Furlott J.R., Kim Y.I., Veloso de Santana M.G., Rakasz E., Capuano S., Wilson N.A., Bonaldo M.C., Galler R., Allison D.B., Piatak M., Haase A.T., Lifson J.D., Allen T.M., Watkins D.I. Vaccine-induced CD8+ T cells control AIDS virus replication. Nature 2012, 491:129-133.
42. Nimmerjahn F., Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 2008, 8:34-47.
43. Patterson L.J., Malkevitch N., Pinczewski J., Venzon D., Lou Y., Peng B., Munch C., Leonard M., Richardson E., Aldrich K., Kalyanaraman V.S., Pavlakis G.N., Robert-Guroff M. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120. J. Virol. 2003, 77:8607-8620.
44. Patterson L.J., Malkevitch N., Venzon D., Pinczewski J., Gomez-Roman V.R., Wang L., Kalyanaraman V.S., Markham P.D., Robey F.A., Robert-Guroff M. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J. Virol. 2004, 78:2212-2221.
45. Patterson L.J., Daltabuit-Test M., Xiao P., Zhao J., Hu W., Wille-Reece U., Brocca-Cofano E., Kalyanaraman V.S., Kalisz I., Whitney S., Lee E.M., Pal R., Montefiori D.C., Dandekar S., Seder R., Roederer M., Wiseman R.W., Hirsch V., Robert-Guroff M. Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge. Virology 2011, 411:87-102.
46. Patterson L.J., Kuate S., Daltabuit-Test M., Li Q., Xiao P., McKinnon K., DiPasquale J., Cristillo A., Venzon D., Haase A., Robert-Guroff M. Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route. Clin. Vaccine Immunol. 2012, 19:629-637.
47. Peruchon S., Chaoul N., Burelout C., Delache B., Brochard P., Laurent P., Cognasse F., Prevot S., Garraud O., Le Grand R., Richard Y. Tissue-specific B-cell dysfunction and generalized memory B-cell loss during acute SIV infection. PLoS One 2009, 4:e5966.
48. Querec T., Bennouna S., Alkan S., Laouar Y., Gorden K., Flavell R., Akira S., Ahmed R., Pulendran B. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 2006, 203:413-424.
49. Rhee E.G., Blattman J.N., Kasturi S.P., Kelley R.P., Kaufman D.R., Lynch D.M., La Porte A., Simmons N.L., Clark S.L., Pulendran B., Greenberg P.D., Barouch D.H. Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors. J. Virol. 2011, 85:315-323.
50. Robert-Guroff M., Kaur H., Patterson L.J., Leno M., Conley A.J., McKenna P.M., Markham P.D., Richardson E., Aldrich K., Arora K., Murty L., Carter L., Zolla-Pazner S., Sinangil F. Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus. J. Virol. 1998, 72:10275-10280.
51. Robinson H.L. Non-neutralizing antibodies in prevention of HIV infection. Expert Opin. Biol. Ther. 2013, 13:197-207.
52. Romano J.W., Shurtliff R.N., Dobratz E., Gibson A., Hickman K., Markham P.D., Pal R. Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology. J. Virol. Methods 2000, 86:61-70.
53. Schenten D., Medzhitov R. The control of adaptive immune responses by the innate immune system. Adv. Immunol. 2011, 109:87-124.
54. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A., Racz P., Tenner-Racz K., Dalesandro M., Scallon B.J., Ghrayeb J., Forman M.A., Montefiori D.C., Rieber E.P., Letvin N.L., Reimann K.A. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999, 283:857-860.
55. Seder R.A., Paul W.E. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu. Rev. Immunol. 1994, 12:635-673.
56. Sodroski J.G. HIV-1 entry inhibitors in the side pocket. Cell 1999, 99:243-246.
57. Sundling C., O'Dell S., Douagi I., Forsell M.N., Morner A., Lore K., Mascola J.R., Wyatt R.T., Hedestam G.B.K. Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus. J. Virol. 2010, 84:9086-9095.
58. Suurmond J., Stoop J.N., Rivellese F., Bakker A.M., Huizinga T.W.J., Toes R.E.M. Activation of human basophils by combined toll-like receptor- and FcεRI-triggering can promote Th2 skewing of naïve T helper cells. Eur. J. Immunol. 2014, 44:386-396.
59. Thomas M.A., Song R., Demberg T., Vargas-Inchaustegui D.A., Venzon D., Robert-Guroff M. Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors. PLoS One 2013, 8:e76344.
60. Titanji K., De Milito A., Cagigi A., Thorstensson R., Grutzmeier S., Atlas A., Hejdeman B., Kroon F.P., Lopalco L., Nilsson A., Chiodi F. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 2006, 108:1580-1587.
61. Xiao P., Zhao J., Patterson L.J., Brocca-Cofano E., Venzon D., Kozlowski P.A., Hidajat R., Demberg T., Robert-Guroff M. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J. Virol. 2010, 84:7161-7173.
62. Xiao P., Patterson L.J., Kuate S., Brocca-Cofano E., Thomas M.A., Venzon D., Zhao J., DiPasquale J., Fenizia C., Lee E.M., Kalisz I., Kalyanaraman V.S., Pal R., Montefiori D., Keele B.F., Robert-Guroff M. Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge. J. Virol. 2012, 86:4644-4657.
63. Zhao J., Lou Y., Pinczewski J., Malkevitch N., Aldrich K., Kalyanaraman V.S., Venzon D., Peng B., Patterson L.J., Edghill-Smith Y., Woodward R., Pavlakis G.N., Robert-Guroff M. Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants. Vaccine 2003, 21:4022-4035.